28th Annual Meeting of the German Society for Human Genetics (GfH) - Bochum, Germany

29 - 31 March 2017

Join us for the 28th annual meeting of the German Society for Human Genetics. The GfH, founded in 1987, is the primary professional membership organization for human geneticists in Germany. With more than 1000 professional members, the GfH Society brings a diverse group of researchers together including academics, clinicians, laboratory practice professionals, genetic counselors and others involved in or with special interest in human genetics. We will be hosting a Technical Workshop entitled Getting the Most out of RNA-Seq by Douglas Amorese. 

Getting the Most out of RNA-Seq

Location: Hörsaalzentrum Ost (HZO), HZO 60
When: 30 March 2017 - 12:00PM

12:00PM
Douglas Amorese, PhD, CSO

NuGEN Technologies, Inc.

While RNA-Seq has become a common method for studying biological changes, it should not be thought of as a single tool but rather a customizable tool that could be tailored to specific needs.  In some cases the primary interest is in very specific genes along a particular pathway so a targeted approach is warranted, in other cases understanding expression levels of all coding transcripts is important so one can enrich for polyadenylated transcripts, in other situations there may be equal interest in looking at regulatory transcripts so whole transcriptome RNA-Seq may be more appropriate.  In the case of cfRNA, the method needs to work well with very small amounts of partially degraded RNAs and in other cases the biological sample may be heavily contaminated with microbial transcripts or perhaps the interest is in the microbe and the contaminant is the host.  NuGEN has developed an array of technologies to address the specific needs of the researcher from both a starting material and information desired perspective.  This talk will describe some of the technologies developed to maximize the information obtainable from different sample types.  These include; SPET – a target enrichment technology, AnyDeplete - a technology that depletes “uninformative” elements from an NGS library, SoLo - a technology developed specifically to work with single or small numbers of cells, and SPIA – a technology developed to amplify small amounts of degraded RNA so they can be better represented in an NGS library.

X
Douglas Amorese, PhD, CSO

NuGEN Technologies, Inc.

Doug serves as Chief Scientific Officer for NuGEN and brings a wealth of experience and knowledge to the role as an accomplished leader in the development and commercialization of complex systems for nucleic acid analysis. He has extensive experience with microarray and DNA sequencing technologies, and has successfully directed a robust expansion of NuGEN’s product portfolio, including the introduction of novel sample preparation technologies for next-gen sequencing applications.  Prior to NuGEN, Doug led the research and development organization for Agilent Genomics. He has also held positions with DuPont and Life Technologies. Doug earned a PhD in biochemistry at Colorado State University, and served post-doctoral fellowships at the Salk Institute and at the University of Texas Health Science Center.  He is an avid bicyclist, and has used his bicycle as his primary mode of commuting for over 30 years.  Doug also volunteers at the local high school and enjoys woodworking in his spare time.